Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non Operating Income (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Non Operating Income for 10 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 102.68% to $57000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 80.46% decrease, with the full-year FY2025 number at $1.3 million, down 75.91% from a year prior.
  • Non Operating Income was $57000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $275000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $100.2 million in Q1 2021 to a low of -$2.4 million in Q1 2025.
  • A 5-year average of $6.0 million and a median of $76000.0 in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 8716.37% in 2021, then tumbled 845.33% in 2024.
  • Rhythm Pharmaceuticals' Non Operating Income stood at $447000.0 in 2021, then crashed by 187.25% to -$390000.0 in 2022, then surged by 42.31% to -$225000.0 in 2023, then crashed by 845.33% to -$2.1 million in 2024, then surged by 102.68% to $57000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Non Operating Income are $57000.0 (Q4 2025), $275000.0 (Q3 2025), and $3.3 million (Q2 2025).